


**Amendments to the Claims:**

*This listing of claims will replace all prior versions, and listings, of claims in the application:*

**Listing of Claims:**

1. (Currently Amended) A compound according to the general Formula (I)



the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, wherein :

- n is an integer, equal to 1;
- m is an integer, equal to 1;
- p is an integer equal to 1 or 2;
- q is an integer equal to 0;

Q is O;

X is a covalent bond;

~~each R<sup>2</sup> independently from each other, is hydrogen or alkyl ;~~

each R<sup>1</sup> independently from each other, is selected from the group of Ar<sup>1</sup>, Ar<sup>1</sup>-alkyl and di(Ar<sup>1</sup>)-alkyl ;

R<sup>2</sup> is Ar<sup>2</sup>;

Y is a covalent bond or a bivalent radical of formula -C(=O)-, -SO<sub>2</sub>-, >C=CH-R or >C=N-R, wherein R is H , CN or nitro ;

- each Alk represents, independently from each other, a covalent bond ; a bivalent straight or branched, saturated or unsaturated hydrocarbon radical having from 1 to 6 carbon atoms ; or a cyclic saturated or unsaturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more , phenyl, halo, cyano, hydroxy, formyl and amino radicals;
- L is selected from the group of hydrogen, alkyl, alkyloxy, alkyloxyalkyloxy, alkylcarbonyloxy, alkyloxycarbonyl, mono- and di(alkyl)amino, mono- and di(alkyloxycarbonyl)amino, mono- and di(alkylcarbonyl)amino, mono-and di(Ar<sup>3</sup>)amino, mono-and di(Ar<sup>3</sup>alkyl)amino, mono-and di(Het<sup>2</sup>)amino, mono-and di(Het<sup>2</sup>alkyl)amino, alkylsulfanyl, adamantyl, Ar<sup>3</sup>, Ar<sup>3</sup>-oxy, Ar<sup>3</sup>carbonyl, Het<sup>2</sup>, Het-oxy and Het<sup>2</sup>carbonyl;
- Ar<sup>1</sup> is phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, alkyl, cyano, aminocarbonyl and alkyloxy ;
- Ar<sup>2</sup> is naphthalenyl or phenyl, each optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, nitro, amino, mono- and di(alkyl)amino, cyano, alkyl, hydroxy, alkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl and mono- and di(alkyl)aminocarbonyl ;
- Ar<sup>3</sup> is naphthalenyl or phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of alkyloxy, Ar<sup>1</sup>carbonyloxyalkyl, Ar<sup>1</sup>alkyloxycarbonyl, Ar<sup>1</sup>alkyloxyalkyl, alkyl, halo, hydroxy, pyridinyl, morpholinyl, pyrrolidinyl, imidazo[1,2-*a*]pyridinyl, morpholinylcarbonyl, pyrrolidinylcarbonyl, amino and cyano;
- Het<sup>2</sup> is a monocyclic heterocyclic radical selected from the group of pyrrolidinyl, dioxolyl, imidazolidinyl, pyrazolidinyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, imidazolidinyl, tetrahydrofuranyl, 2H-pyrrolyl, pyrrolinyl, imidazolinyl, pyrazolinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thienyl, oxazolyl, dioxazolyl, oxazolidinyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyrimidinyl,

pyrazinyl, pyridazinyl and triazinyl ;  
 or a bicyclic heterocyclic radical selected from the group of 2,3-dihydro-benzo[1,4]dioxine, octahydro-benzo[1,4]dioxine, benzopiperidinyl, quinolinyl, quinoxalinyl, indolyl, isoindolyl, chromanyl, benzimidazolyl, imidazo[1,2-*a*]pyridinyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl or benzothieryl ;  
 or the tricyclic heterocyclic radical 8,9-dihydro-4*H*-1-oxa-3,5,7*a*-triazacyclopenta[*f*]azulenyl ; each radical may optionally be substituted with one or more radicals selected from the group of Ar<sup>1</sup>, Ar<sup>1</sup>alkyl, Ar<sup>1</sup>alkyloxyalkyl, halo, hydroxy, alkyl, piperidinyl, pyrrolyl, thienyl, oxo, alkyloxy, alkylcarbonyl, Ar<sup>1</sup>carbonyl, mono- and di(alkyl)aminoalkyl, alkyloxyalkyl and alkyloxycarbonyl; and

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms ; optionally substituted on one or more carbon atoms with one or more radicals selected from the group of phenyl, halo, cyano, oxo, hydroxy, formyl and amino.

2. (Previously amended) A compound according to claim 1 wherein :

R<sup>1</sup> is Ar<sup>1</sup>-alkyl;

R<sup>2</sup> is Ar<sup>2</sup>;

Y is a covalent bond or a bivalent radical of formula -C(=O)-, -SO<sub>2</sub>-, >C=CH-R or >C=N-R, wherein R is CN or nitro ;

each Alk represents, independently from each other, a covalent bond ; a bivalent straight or branched, saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; each radical optionally substituted on one or more carbon atoms with one or more phenyl, halo and hydroxy radicals;

L is selected from the group of hydrogen, alkyl, alkyloxy, alkyloxyalkyloxy, alkylcarbonyloxy, mono- and di(alkyl)amino, mono- and di(alkyloxycarbonyl)amino, mono- and di(alkylcarbonyl)amino, mono-and di(Ar<sup>3</sup>)amino, mono-and di(Ar<sup>3</sup>alkyl)amino, mono-and di(Het<sup>2</sup>alkyl)amino,

- alkylsulfanyl, adamantyl, Ar<sup>3</sup>, Het<sup>2</sup> and Het<sup>2</sup>carbonyl;
- Ar<sup>1</sup> is phenyl, optionally substituted with 1 or 2 halo radicals ; Ar<sup>2</sup> is naphthalenyl or phenyl, each optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, alkyl and alkyloxy;
- Ar<sup>3</sup> is naphthalenyl or phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of alkyloxy, Ar<sup>1</sup>alkyloxy, Ar<sup>1</sup>alkyloxyalkyl, alkyl, halo and cyano;
- Het<sup>2</sup> is a monocyclic heterocyclic radical selected from the group of pyrrolidinyl, dioxolyl, piperidinyl, morpholinyl, piperazinyl, tetrahydrofuranyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, dioxazolyl, oxazolidinyl, isoxazolyl, thiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocyclic radical selected from the group of 2,3-dihydro-benzo[1,4]dioxine, octahydro-benzo[1,4]dioxine, quinoxalinyl, indolyl, chromanyl, benzimidazolyl, imidazo[1,2-*a*]pyridinyl, benzisoxazolyl, benzothiazolyl, benzofuranyl and benzothienyl ; or the tricyclic heterocyclic radical 8,9-dihydro-4*H*-1-oxa-3,5,7a-triazacyclopenta[*f*]azulenyl ; each radical may optionally be substituted with one or more radicals selected from the group of Ar<sup>1</sup>, Ar<sup>1</sup>alkyloxyalkyl, halo, alkyl, oxo, alkyloxy, alkylcarbonyl, Ar<sup>1</sup>carbonyl, mono- and di(alkyl)aminoalkyl, alkyloxyalkyl and alkyloxyalkyl ; and
- alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms ; optionally substituted on one or more carbon atoms with one or more radicals selected from the group of phenyl, halo and hydroxy.

3. (Previously presented) A compound according to claim 1, wherein R<sup>1</sup> is Ar<sup>1</sup>methyl and attached to the 2-position or R<sup>1</sup> is Ar<sup>1</sup> and attached to the 3-position.
4. (Previously presented) A compound according to claim 1, wherein R<sup>2</sup>-X-C(=Q)-moiety is 3,5-di-(trifluoromethyl) phenylcarbonyl.

5. (Canceled)
6. (Previously presented) A compound according to claim 1, wherein Y is -C(=O)-.
7. (Previously presented) A compound according to claim 1, wherein Alk is a covalent bond.
8. (Previously presented) A compound according to claim 1, wherein L is Het<sup>2</sup>.
9. (Previously presented) A compound according to claim 1, selected from the group consisting of:

[2R-trans]-{2-benzyl-4-[4-(1-pyrazin-2-yl-pyrrolidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone<sub>2</sub>

[2R-[2 $\alpha$ ,4 $\beta$ (S)]]-1-(3-{4-[2-benzyl-1-(3,5-bis-trifluoromethyl-benzoyl)-piperidin-4-yl]-piperazin-1-yl}-pyrrolidin-1-yl)-2,2-dimethyl-propan-1-one<sub>2</sub>

[2R-[2 $\alpha$ ,4 $\beta$ (S\*)]]-2-benzyl-4-[4-(1-cyclopropanecarbonyl-pyrrolidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone<sub>2</sub>

[2R-trans]-enantiomer of {2-benzyl-4-[4-(1-cyclopropanecarbonyl-pyrrolidin-3-yl)-piperazin-1-yl]-piperidin-1-yl}-(3,5-bis-trifluoromethyl-phenyl)-methanone<sub>2</sub>

2R-trans-(2-benzyl-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone<sub>2</sub>

[2R-[2 $\alpha$ ,4 $\beta$ (R(R))]]-(2-benzyl-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone<sub>2</sub>

[2R-[2 $\alpha$ ,4 $\beta$ (S(R))]]-(2-benzyl-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone<sub>2</sub>

[2R-trans, R\*]-(2-benzyl-4-{4-[1-(furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone<sub>2</sub>

[2R-[2 $\alpha$ ,4 $\beta$ (R)]]-(2-benzyl-4-{4-[1-(5-methyl-thiophene-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone<sub>2</sub>

[2R-trans]-(2-benzyl-4-{4-[1-(3-hydroxymethyl-thiophene-2-sulfonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-bis-trifluoromethyl-phenyl)-methanone<sub>2</sub>

[2R-[2 $\alpha$ ,4 $\beta$ (S)]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(4-hydroxy-butyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone<sub>2</sub>

[(2R-trans),(S)]-1-(3-{4-[1-(3,5-bis-trifluoromethyl-benzoyl)-2-(3,4-dichloro-benzyl)-piperidin-4-yl]-piperazin-1-yl}-pyrrolidin-1-yl)-2,2-dimethyl-propan-1-one<sub>2</sub>

trans-(3,5-bis-trifluoromethyl-phenyl)-[4-{4-[1-(2-chloro-benzoyl)-pyrrolidin-3-yl]-piperazin-1-yl}-2-(3,4-dichloro-benzyl)-piperidin-1-yl]-methanone<sub>2</sub>

[(2R-trans),(S)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(thiophene-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone<sub>2</sub>

[(2R-trans), (R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(thiophene-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone<sub>2</sub>

[(2R-trans), (R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(furan-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[(2R-trans), (S)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(furan-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[(2R-trans), (S), (R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[(2R-trans), (R)]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-dichloro-benzyl)-4-{4-[1-(pyrazine-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[2R-[2 $\alpha$ ,4 $\beta$ (R\*)]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(methyl-1H-pyrrole-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[2R-[2 $\alpha$ ,4 $\beta$ (R\*(S\*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[2R-[2 $\alpha$ ,4 $\beta$ (S\*(S\*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[2R-[2 $\alpha$ ,4 $\beta$ (S\*(R\*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[2R-[2 $\alpha$ ,4 $\beta$ (R\*(R\*))]]-(3,5-bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(tetrahydro-furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[2R-[2 $\alpha$ ,4 $\beta$ (S\*)]]-(3,5-Bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(furan-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[2R-[2 $\alpha$ ,4 $\beta$ (S\*)]]-(3,5-Bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(pyrazine-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone,

[2R-[2 $\alpha$ ,4 $\beta$ (S\*)]]-(3,5-Bis-trifluoromethyl-phenyl)-(2-(3,4-difluoro-benzyl)-4-{4-[1-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone, and

cis-(3,5-Bis-trifluoromethyl-phenyl)-(3-phenyl-4-{4-[1-(thiophene-2-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-methanone.

10. (Cancelled)

11. (Canceled)

12. (Canceled)


13. (Previously presented) A method for treating schizophrenia, emesis, anxiety, depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pain, neurogenic inflammation, asthma, micturition disorders and nociception in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to claim 1.

14. (Previously presented) A pharmaceutical composition comprising a




pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1.

15. (Previously presented) A process for preparing a pharmaceutical composition as claimed in claim 14, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as claimed claim 1.
16. (Original) A process for the preparation of a compound of Formula (I'') in which an intermediate compound of Formula (II) is reacted with an intermediate compound of Formula (III), wherein the radicals  $R^2$ , X, Q,  $R^1$ , m, n, p and q are as defined in claim 1.



17. (Original) A process for the preparation of a compound of Formula (I') in which a final compound of Formula (I'') is reductively hydrogenated, wherein the radicals  $R^2$ , X, Q,  $R^1$ , m, n, p and q are as defined in claim 1.



18. (Canceled)